oxbryta
oxbryta: developed by 1 company · 2 FDA decisions. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Global Blood Therapeutics, Inc. (GBT) | Approved |
FDA Decisions
Frequently asked questions
Who is developing oxbryta?
oxbryta is being developed by Global Blood Therapeutics, Inc..
What is oxbryta's latest FDA decision?
The most recent tracked FDA decision for oxbryta is Approval for 1 INDICATIONS AND USAGE OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin (Hb) [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). OXBRYTA is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle , dated December 17, 2021.
Get deeper analysis on oxbryta
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis